Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of First-Line Cadonilimab Plus Axitinib in Patients With Advanced Special Pathological Type Renal Cell Carcinoma: A Prospective, Multi-center, Phase Ib/II Trial

Next Previous
Trial Profile

Efficacy and Safety of First-Line Cadonilimab Plus Axitinib in Patients With Advanced Special Pathological Type Renal Cell Carcinoma: A Prospective, Multi-center, Phase Ib/II Trial

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Cadonilimab (Primary)
  • Indications Adenocarcinoma; Renal cell carcinoma; Sarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 26 May 2026 According to an Akeso Biopharma media release, data from this study will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, Illinois.
  • 07 Apr 2026 Primary endpoint Phase Ib Safety Assessment has been amended. status changed from recruiting to active, no longer recruiting.
  • 07 Apr 2026 Planned End Date changed from 1 Dec 2025 to 1 Jun 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top